CAR-T Cell Therapy

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Chimeric antigen receptor-modified T cell (CART) therapy has heralded a revolution in cancer immunotherapy. Yet, understanding the …

Fiorenza S, Zheng Y , Sarthy J, Sheih A, Kimble E, Kirchmeier D, Janssens D, Phi T, Gauthier J, Hirayama A, Wu Q, Gottardo R, Riddell S, Maloney D, Henikoff S, Turtle C

Cellular profiling of leukapheresis and infusion products of patients enrolled in CD19 CAR T cell therapy identifies biomarkers associated with clinical outcomes

CD19 CAR T cell therapy has emerged as a promising therapy in the treatment of B cell malignancies, such as B cell acute lymphoblastic …

Chour T, Hirayama A, Zheng Y , Sheih A, Zhuang S, Wilson A, Wu V, Gottardo R, Turtle C, Gardner R, Newell E